Serial No.: 09/836.169

(New) The method of claim 38, wherein said endonuclease recognition site has been introduced into said cell by retroviral insertion.

41. (New) The method of claim 38, wherein said organism is yeast.

(New) The method of claim 38, wherein said organism is bacteria.

43. (New) The method of claim 38, wherein said organism is a mammal.

744. (New) A method for *in vivo* site directed genetic recombination in an organism comprising:

- (a) providing a transgenic cell having at least one Group I intron encoded endonuclease recognition site inserted at a unique location in a chromosome;
- (b) providing an expression vector that expresses said endonuclease in said transgenic cell;
- (c) providing a plasmid comprising a gene of interest and a DNA sequence homologous to the sequence of the chromosome, allowing homologous recombination;
 - (d) transfecting said transgenic cell with said plasmid of step (c);
 - (e) expressing said endonuclease from said expression vector in said cell; and
- (f) cleaving said at least one Group I intron encoded endonuclease recognition site with said endonuclease, whereby said cleavage promotes the insertion of said gene of interest into said chromosome of said organism at a specific site by homologous recombination.

DUNNER些

1300 I Street, NW Vashington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com





(New) The method of claim 44, wherein said endonuclease recognition site has been introduced into said cell by homologous recombination.

46. (New) The method of claim 44, wherein said endonuclease recognition site has been introduced into said cell by retroviral insertion.

(New) The method of claim 44, wherein said organism is yeast.

(New) The method of claim 44, wherein said organism is bacteria.

1349. (New) The method of claim 44, wherein said organism is a mammal.

(New) The method of claim 44, wherein said endonuclease recognition site is selected from the group consisting of Class I I-endonuclease sites, Class II I-endonuclease sites, Class IV I-endonuclease sites, and Class V I-endonuclease sites.

(New) The method of claim 50, wherein said endonuclease recognition site is a Class I I-endonuclease site.

(New) The method of claim 51, wherein said endonuclease recognition site is selected from the group consisting of I-Scel, I-ScelV, I-Csml, and I-Panl sites.

53. (New) The method of claim 52, wherein said endonuclease recognition site is an I-Scel site.

1754. (New) The method of claim 44, wherein said endonuclease recognition site is an I-SceIV site.

55. (New) The method of claim 44, wherein said endonuclease recognition site is an I-Csml site.

CZ Cont.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com





56. (New) The method of claim 44, wherein said endonuclease recognition site is an I-PanI site.

(New) The method of claim 44, wherein said endonuclease recognition site is an I-Scell site.

58. (New) The method of claim 44, wherein said endonuclease recognition site is an I-Ceul site.

59. (New) The method of claim 44, wherein said endonuclease recognition site is an I-Ppol site.

2760. (New) The method of claim 44, wherein said endonuclease recognition site is an I-ScellI site.

2 (New) The method of claim 44, wherein said endonuclease recognition site is an I-Crel site.

(New) The method of claim 44, wherein said endonuclease recognition site is an I-TevI site.

(New) The method of claim 44, wherein said endonuclease recognition site is an I-TevII site.

site is an I-TevIII site.

FINNEGAN HENDERSON FARABOW GARRETT &

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

REMARKS

Reconsideration of this application is respectfully requested. The first paragraph of the specification has been amended, and now recites U.S. Patent Nos.

84